-Wall Street Journal
Merck And Ridgeback Announce Submission Of Emergency Use Authorization Application To The U.S. FDA For Molnupiravir, An Investigational Oral Antiviral Medicine, For The Treatment Of Mild-to-moderate COVID-19 In At Risk Adults
Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today announced that Merck has submitted an Emergency Use Authorization (EUA) application to the U.S. Food and Drug
